• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats

    11/21/25 1:35:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ELAN alert in real time by email

    EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options

    • First U.S. Food and Drug Administration Emergency Use Authorization (EUA) granted for New World screwworm in cats, reinforcing Elanco's leadership in feline innovation
    • Action reinforces the FDA's commitment to act swiftly against emerging animal health threats
    • Scientific studies showed Credelio CAT may be effective in treating New World screwworm in catsi,ii
    • Preventing open wounds through effective flea and tick control is critical in protecting pets from NWS

    INDIANAPOLIS, Nov. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Credelio™ CAT (lotilaner) to treat New World screwworm (NWS) infestations in cats. This authorization represents the first EUA granted by the FDA for New World screwworm treatment in felines.

    Elanco logo (PRNewsfoto/Elanco Animal Health)

    With confirmed cases of New World screwworm detected as close as 70 miles south of the U.S.-Mexico border,iii this EUA ensures veterinarians and pet owners have a ready-now treatment option for cats and kittens should the fly enter the U.S.

    "The FDA's swift and thorough evaluation of the scientific evidence showing Credelio CAT's potential effectiveness against New World screwworm in cats is greatly appreciated," said Dr. Ellen de Brabander, Executive Vice President of Innovation and Regulatory Affairs at Elanco. "As a leader in feline health, Elanco is committed to ensuring cats receive complementary innovative solutions to those available to dogs. This historic EUA equips veterinarians and cat owners with a treatment solution and provides reassurance that they're prepared to act quickly if New World screwworm crosses into the U.S."

    Elanco's commitment to feline innovation addresses an important gap in companion animal care. Cats have historically had fewer products and treatment options available compared to dogs, and research shows this disparity extends to veterinary visits—with over 90% of dog owners taking their pets to the veterinarian compared to only 40% of cat owners.iv This EUA ensures that cats have a treatment option on par with their canine counterparts when facing this emerging health threat.

    The Emergency Use Authorization was based on research evaluating the efficacy of Credelio CAT against Old World screwworm in cats as well as the efficacy of Credelio against New World screwworm in dogs.

    Elanco's Credelio franchise has made significant strides in animal health. Last month, Credelio™ (lotilaner) received the first-ever FDA Emergency Use Authorization for treating NWS in dogs, which is the first time ever that the FDA has issued an EUA for an animal drug. Now, with this EUA for Credelio CAT, the franchise demonstrates its comprehensive approach for providing solutions for both dogs and cats for this emerging threat.

    Before New World screwworm reaches the United States, veterinarians and pet owners can take proactive steps to prevent wounds that can create ideal conditions for New World screwworm infection. New World screwworm infestations begin when a female New World screwworm fly lays eggs on open wounds or other parts of the body in live, otherwise healthy, warm-blooded animals. According to the Centers for Disease Control, wounds as small as a tick bite may attract a female fly to feed and lay her eggs. One female can lay 200 – 300 eggs at a time and may lay up to 3,000 eggs during her 10- to 30-day lifespan.v Unlike most fly species whose larvae may feed on dead and decaying tissue, New World screwworm larvae burrow into the flesh of living animals, causing severe tissue damage and even death if left untreated.

    The U.S. Animal Plant Health and Inspection Service (APHIS) recommends that one way to prevent New World screwworm infestations is to protect pets and livestock from other wound-causing parasites such as flies and ticks.vi

    "Given New World screwworm's aggressive and invasive nature, any minor wounds from grooming, scratching, or outdoor activities can serve as an entry point for these parasites," said Dr. Casey Locklear, Texas-based veterinarian and parasiticide lead at Elanco. "It's essential to prevent or quickly address any wounds to keep cats safe from New World screwworm. Year-round flea and tick protection, like Credelio CAT, helps minimize self-inflicted scratching that could create vulnerable sites."

    Learn more about Credelio CAT here.

    To learn more about NWS, the following resources are available:

    • FDA Information for Veterinarians on New World Screwworm 
    • USDA NWS Alert and Fact Sheet

    ABOUT ELANCO

    Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our purpose – all to Go Beyond for Animals, Customers, Society and Our People. Learn more at www.elanco.com.

    Emergency Use Authorization for Credelio CAT (lotilaner) for New World Screwworm (NWS)

    The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio CAT (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in cats and kittens. Credelio CAT is not approved for this use. 

    Credelio CAT is approved for other uses. 

    For additional information on the EUA, please refer to the Credelio Cat NWS Fact Sheet.

    Limitations of Authorized Use

    Credelio CAT (lotilaner) is authorized for this use only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio CAT (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

    CREDELIO CAT APPROVED INDICATIONS

    Credelio CAT kills adult fleas and is indicated for the treatment and prevention of flea infestations for one month in cats and kittens 8 weeks of age and older and weighing 2 pounds or greater. 

    Credelio CAT is also indicated for treatment and control of black-legged tick infestations for one month in cats and kittens 6 months of age and older and weighing 2 pounds or greater. 

    CREDELIO CAT IMPORTANT SAFETY INFORMATION

    Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio CAT has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio CAT against black-legged ticks in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, rapid breathing and vomiting. For complete safety information, please see Credelio CAT product label or ask your veterinarian. 

    Emergency Use Authorization for Credelio (lotilaner) for New World screwworm (NWS)

    The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the approved product Credelio (lotilaner) for the treatment of infestations caused by NWS (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies. However, Credelio is not approved for this use.

    Credelio is approved for other uses.

    For additional information on the EUA, please refer to the Credelio NWS Fact Sheet.

    Limitations of Authorized Use

    Credelio (lotilaner) is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of Credelio (lotilaner) under section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

    CREDELIO APPROVED INDICATIONS

    Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations and treatment and control of tick infestations (lone star tick, American dog tick, black-legged tick, brown dog tick, and longhorned tick) for one month in dogs and puppies 8 weeks and older and 4.4 pounds or greater. Credelio is indicated for the prevention of Lyme disease infections as a direct result of killing black-legged ticks.

    CREDELIO IMPORTANT SAFETY INFORMATION

    Lotilaner is a member of the isoxazoline class of drugs. This class has been associated with neurologic adverse reactions including tremors, incoordination, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, increased urination, and diarrhea. For complete safety information, please see Credelio product label or ask your veterinarian.

    Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2025 Elanco or its affiliates

    PM-US-25-2228 

    i Han, HS, Yasmin, L (2020). Chrysomya bezziana (Diptera: Calliphoridae) infestation in two Malaysian cats treated with oral lotilaner. Vet Dermatol, 31:335-e87

    ii do Vale, T.L., Costa, A.R., Miranda, L.M. et al. Efficacy of lotilaner against myiasis caused by Cochliomyia hominivorax (Diptera: Calliphoridae) in naturally infested dogs. Parasites Vectors 16, 86 (2023). https://doi.org/10.1186/s13071-023-05661-z

    iii
     Mexico Confirms Case of New World Screwworm in Nuevo Leon | Animal and Plant Health Inspection Service

    iv Familiarity and Use of Veterinary Services by US Resident Dog and Cat Owners - PMC

    v About New World Screwworm Myiasis | Myiasis | CDC

    vi APHIS, New World Screwworm

    Investor Contact: Tiffany Kanaga (765) 740-0314 [email protected]

    Media Contact: Season Solorio (765) 316-0233 [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/elancos-credelio-cat-lotilaner-receives-first-fda-emergency-use-authorization-eua-for-treatment-of-new-world-screwworm-nws-in-cats-302623496.html

    SOURCE Elanco Animal Health

    Get the next $ELAN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN

    DatePrice TargetRatingAnalyst
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    11/19/2025$25.00Hold → Buy
    Argus
    10/7/2025$24.00Neutral → Overweight
    Analyst
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    6/26/2025Mkt Perform → Outperform
    William Blair
    12/9/2024$18.00Buy
    UBS
    12/2/2024$14.00Market Perform
    Leerink Partners
    9/19/2024$17.00 → $15.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ELAN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats

    EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First U.S. Food and Drug Administration Emergency Use Authorization (EUA) granted for New World screwworm in cats, reinforcing Elanco's leadership in feline innovationAction reinforces the FDA's commitment to act swiftly against emerging animal health threatsScientific studies showed Credelio CAT may be effective in treating New World screwworm in catsi,iiPreventing open wounds through effective flea and tick control is critical in protecting pets from NWSINDIANAPOLIS, Nov. 21, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today an

    11/21/25 1:35:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco to Participate in the Upcoming Investor Conferences

    INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, December 3, Jeff Simmons, president and CEO, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference at 12:30 p.m. ET. On Thursday, December 4, Bob VanHimbergen, executive vice president and CFO, and Bobby Modi, executive vice president, US Pet Health and Global Digital Transformation, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare

    11/20/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health

    Alloy Partners, Elanco and other corporate partners join forces to develop new venture studio INDIANAPOLIS, Nov. 13, 2025 /PRNewswire/ -- Alloy Partners today announced the launch of OneHealth Studio, a first-of-its-kind venture studio designed specifically to create and scale new companies at the convergence of animal, plant and human health in partnership with Elanco Animal Health (NYSE:ELAN). Located in the OneHealth Innovation District at Elanco's new global headquarters in Indianapolis, the studio will unite research institutions, investors, corporate partners and entrep

    11/13/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/11/25 5:13:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/7/25 4:21:21 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    8/26/24 5:05:35 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on Elanco Animal Health with a new price target

    KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00

    11/21/25 8:08:36 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Argus with a new price target

    Argus upgraded Elanco Animal Health from Hold to Buy and set a new price target of $25.00

    11/19/25 9:01:05 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health upgraded by Analyst with a new price target

    Analyst upgraded Elanco Animal Health from Neutral to Overweight and set a new price target of $24.00

    10/7/25 8:46:24 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Officer Modi Rajeev A.

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    11/18/25 4:46:31 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    11/18/25 4:46:04 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    11/4/25 4:38:09 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Financials

    Live finance-specific insights

    View All

    Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., Oct. 1, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2025 financial results on Wednesday, November 5, 2025. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de

    10/1/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Reports Second Quarter 2025 Results

    Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2025 Financial Results:Revenue of $1,241 million, an increase of 5% year-over-year; 8% organic constant currency growthReported Net Income of $11 million, Adjusted Net Income of $131 millionAdjusted EBITDA of $238 million; Adjusted EBITDA Margin of 19.2% Reported EPS of $0.02, Adjusted EPS of $0.26Net leverage ratio of 4.0x Adjusted EBITDAFull Year 2025 Guidance:Raising revenue guidance to $4,570 to $4,620 million; expect accelerating organic constant currency revenue growth of 5% to 6% vs. 3% in 2024Raising 2025 innovation revenue target by $60 million to $720 to $800 millionReported

    8/7/25 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement

    GREENFIELD, Ind., July 10, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its second quarter 2025 financial results on Thursday, August 7, 2025. Elanco will also conduct a conference call on that day with the investment community and media to provide further details about the company's performance. The conference call will begin at 8:00 a.m. Eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link posted on Elanco's website at https://investor.elanco.com/events-and-presentations/d

    7/10/25 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    SEC Filings

    View All

    SEC Form 10-Q filed by Elanco Animal Health Incorporated

    10-Q - Elanco Animal Health Inc (0001739104) (Filer)

    11/5/25 9:06:32 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    11/5/25 6:30:30 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Elanco Animal Health Inc (0001739104) (Filer)

    11/3/25 7:30:42 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Appoints Robert (Bob) VanHimbergen as Chief Financial Officer

    GREENFIELD, Ind., May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025. VanHimbergen's appointment follows an extensive and competitive search as part of the company's commitment to long-term, sustained value creation. VanHimbergen succeeds Todd Young, who will remain with the company as an advisor through August 31, 2025, to facilitate a smooth transition. VanHimbergen currently serves as the Senior Vice President and Chi

    5/28/25 7:25:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elanco Animal Health Incorporated

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    7/8/24 4:32:39 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/13/24 2:08:55 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Elanco Animal Health Incorporated (Amendment)

    SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)

    2/12/24 4:01:30 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care